Results 171 to 180 of about 77,706 (265)

Endoscopic small bowel therapies for type 2 diabetes

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel   +4 more
wiley   +1 more source

Assessment of the hypoglycemic effect of Cyanthillium cinereum (L.) H. Rob. and its dual impact on uterine contraction in gestational diabetic rats. [PDF]

open access: yesCurr Res Physiol
Kerdsuknirund S   +7 more
europepmc   +1 more source

Outpatient preoperative parenteral nutrition in malnourished surgical patients: A feasibility study (the OPPORTUNITY study)

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Preoperative parenteral nutrition (PN) improves outcomes in malnourished surgical patients. Traditionally, this requires hospital admission, increasing length of stay and costs—challenges worsened by limited hospital bed availability. Outpatient PN may offer a feasible alternative.
Narisorn Lakananurak, Leah Gramlich
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

open access: yesObesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu   +13 more
wiley   +1 more source

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

open access: yesObesity, EarlyView.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo   +4 more
wiley   +1 more source

Oral GLP‐1RA TERN‐601 for Adults With Obesity/Overweight: Placebo‐Controlled, Multiple‐Ascending‐Dose, Phase 1 and 2 Studies

open access: yesObesity, EarlyView.
ABSTRACT Objective The safety, tolerability, pharmacokinetics, and efficacy of TERN‐601, a once‐daily, oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, were studied in Phase 1 and 2 clinical studies. Methods The Phase 1 (28‐day) and Phase 2 (12‐week), randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose studies ...
W. Timothy Garvey   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy